Endocrine Abstracts

Objectives: Optimal treatment for Graves’ hyperthyroidism (GH) in patients with moderate-to-severe, active Graves’ orbitopathy (GO) remains to be established. There is debate on whether a conservative (antithyroid drugs, ATDs) or an ablative approach (radioactive iodine, RAI, or surgery, Tx)has to be preferred. The aim of the present study was to investigate whether these different approachesresult in a different outcome of GOfollowing intravenous glucocorticoids (iv...

Introduction: Grip strength is a valuable biomarker of an individual’s biological age. Weak grip strength is a key component of sarcopenia and frailty and is associated with subsequent poor health, disability and mortality. Skeletal muscle is one of the major target organs of thyroid hormones. Hyperthyroidism may affect skeletal muscles qualitatively and quantitatively, to the extent of developing muscle weakness and myopathy. There are few studies investigating grip stre...

Objectives: Iodine fortification (IF) induces an initial increase followed by a decrease in the incidence of hyperthyroidism in the population. Also, the sex-, age-, and subtype distribution of hyperthyroid cases changes after IF. The risk of atrial fibrillation (AF) in hyperthyroid patients is influenced by these factors. Therefore, we aimed to examine how the association between incident hyperthyroidism and atrial fibrillation was affected by an IF increasing the population ...

Introduction: Graves’ disease is the leading cause of hyperthyroidism in the adult population. Antithyroid drugs (ATD) are the first choice worldwide, however, after an initial treatment course of 18-24 months, almost 40-50% will relapse. In these cases, current guidelines suggest a second course or prolonged use of ATD as an option. Recently, the study of quality of life (QOL) has obtained great importance, since the QOL in hyperthyroid patients is very affected. However...

Objectives: Graves’ disease (GD) is a common cause of hyperthyroidism. An increased heart rate (HR) is a hallmark of elevated thyroid hormones (TH). In a prospective observational study we monitored HR continuously with wearable fitness trackers to evaluate the correlation between HR and TH levels and the relevance of HR monitoring for clinical management of patients with GD.Methods: Seventeen outpatients with newly diagnosed or relapsed GD starting...

Aim: In Graves’ disease (GD) the goal of radioiodine (I-131) application is the elimination of hyperthyroidism. The reported success rate 1 year after treatment is up to 90%. The aim of this retrospective study was to assess the factors influencing the early outcome 3 months after I-131 treatment of GD patients in an iodine sufficient area.Materials and Methods: We reviewed medical records of GD patients who received I-131 therapy between January 20...

Introduction: The choice of treatment for Graves’ disease (GD) requires a comprehensive assessment of the patient’s condition and the risk of recurrence. The aim of our study was to evaluate the association of immunological and genetic markers with GD recurrence after antithyroid treatment.Methods: We conducted a case-control study. The study included 63 patients with GD who received antithyroid treatment. After at least 12 months of withdrawal...

Objectives: Graves’ disease (GD) is characterized by variable disease severity at diagnosis and variable disease activity during follow-up. Antithyroid drugs (ATD) such as carbimazole (CMZ), methimazole or propylthiouracil are the first-line treatment. Current guidelines recommend a range of ATD starting dose according to GD severity, followed by dose titration until euthyroidism is reached and a maintenance dose for a specific patient is established. As thyroid hormones ...

Background: Despite a high relapse rate, antithyroid drugs (ATDs) remain the first-line therapy of Graves’ disease (GD). Long-term follow-up studies of GD in Spain are scarce. Our aims were to identify clinical differences between patients who relapsed vs those who attained remission and to describe the relapse rate of GD after ATD withdrawal.Methods: We analyzed patients with the first episode of GD who were treated with ATDs during 2010 - 2020, in...